Patent Highlight pubs.acs.org/acsmedchemlett
Cite This: ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX
5‑HT2C Receptor Agonists for the Treatment of Obesity Robert B. Kargbo* Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States that are able to distinguish among these receptor subtypes, especially as regards to the differentiation between 5-HT2B and 5-HT2C receptors, has hampered development of drug-based therapy. For instance, the once popular D-fenfluramine drug for the treatment of obesity, acting by enhancement of serotonergic function in the brain, was withdrawn from the U.S. market due to reports of heart valve disease and pulmonary hypertension. Activation of the 5-HT2A receptors leads to a number of adverse central nervous system (CNS) effects, including hallucination and perception. However, activation of the 5-HT2B receptor causes adverse effects in the cardiovascular system, including heart valve disease and pulmonary hypertension. There are very few drugs available for the treatment of obesity. Lorcaserin, classified as a schedule 4 drug (low risk for abuse), was approved by the Food and Drug Administration (FDA) in June 2013. Lorcaserin is an agonist of the 5-HT2C receptor and effective at reducing obesity in humans and animal models. Since lorcaserin affects the serotonin receptors, an adverse effect such as serotonin syndrome can be triggered with drugs or substances that affect levels of serotonin neurotransmitters, including selective serotonin reuptake inhibitors (SSRIs). Tobacco use is the leading cause of preventable illness and early cause of deaths worldwide. According to the United States Centers for Disease Control and Prevention (CDC), the major causes of excess mortality among smokers are diseases that are related to smoking, including cancer and respiratory and vascular diseases. In addition, smokeless tobacco is a known cause of cancer [https://www.cdc.gov/tobacco/data_statistics/fact_ sheets/health_effects/tobacco_related_mortality/index.htm (accessed July 15, 2018)]. The vast majority of smokers may attempt to quit; however, continued abstinences are difficult to achieve. Existing smoking cessation treatments such as Zyban (bupropion SR) and Chantix (varenicleine) have black box warnings such as serious neuropsychiatric events, depressed mood changes, suicidal ideation or suicidal behavior, and so forth. The well-recognized side effects of quitting smoking are bigger appetites, slower metabolism, triggers, and cravings, which may lead to weight gain in about 80% of smoke-free individuals. However, these side effects are considered modest inconveniences compared to the health benefits of smoking cessation. There is possibly a complex relationship between body weight and smoking, in which heavy smokers tend to have higher body weight and a higher likelihood of obesity than lighter smokers. Smoking cessation is a significant unmet need as existing therapies lack long-term success rates. Compounds of this invention modulate the activity of the 5-HT2C receptor and are useful in the treatment of 5-HT2C receptor-mediated disorders like weight management, decreasing
Downloaded via 5.189.207.140 on August 2, 2018 at 13:36:16 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.
Important Compound Classes.
Title. 5-HT2C Receptor Agonists and Compositions and Methods of use Patent Application Number. WO 2018/035477 A1 Publication Date. February 22, 2018 Priority Application. US 62/377,119 Priority Date. August 19, 2016 Inventors. Semple, G.; Ren, A. S.; Schrader, T. O.; Kasem, M.; Zhu, X. Assignee Company. Arena Pharmaceuticals, Inc. Disease Area. Obesity Biological Target. 5-HT2C Receptor Summary. The worldwide prevalence of obesity represents great economical and global human health burden. Major risk factors are coronary heart disease, type II diabetes, heart failure, and stroke, which account for a growing number of worldwide deaths. Conceptually, the prevention and treatment of obesity can be accomplished through diet and exercise. However, many people are unable to attain significant lasting body weight reduction through these methods alone. There is urgent unmet need for drug-based therapy, which may provide an opportunity for patients to achieve clinically beneficial weight loss. Serotonin (5-HT), a major monoamine neurotransmitter found in the central nervous system (CNS), plays an important role in numerous physiological processes. These biological functions are mediated by a variety of serotonin receptors, which constitutes the mechanism of many drug actions. Type 2 serotonin receptors (5-HT2) mediate the actions of many disease processes such as feeding disorders, depression, perception, schizophrenia, anxiety, hallucinations, and so forth. In particular, the three 5-HT2 receptor subtypes (5-HT2A, 5-HT2B, and 5-HT2C) show significant homology at structural, genetic, and functional levels. The regulation of 5-HT for feeding behavior is believed to function by inducing a feeling of satiety in the region of the brain located in the ventromedial nucleus of the hypothalamus and the hunger center present in the lateral hypothalamus. Stimulatory action of 5-HT on the 5-HT2C receptor results in an enhanced 5-HT; the subject stops eating earlier, and fewer calories are consumed. In addition, the 5-HT2C receptor, which is minimally expressed or absent in the peripheral tissues, is a major receptor target for the treatment of obesity, psychiatric disorder, and sexual dysfunction. However, the lack of truly selective ligands © XXXX American Chemical Society
Received: July 20, 2018
A
DOI: 10.1021/acsmedchemlett.8b00328 ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX
ACS Medicinal Chemistry Letters
Patent Highlight
Recent Review Articles. 1. Ikarashi, Y.; Sekiguchi, K.; Mizoguchi, K. Curr. Med. Chem. 2018, 25, 1036. 2. Barros, M. L. D.; Manhães-de-Castro, R.; Alves, D. T.; Quevedo, O. G.; Toscano, A. E.; Bonnin, A.; Galindo, L. Eur. J. Pharmacol. 2018, 833, 298. 3. Palacios, J. M.; Pazos, A.; Hoyer, D. Psychopharmacology 2017, 234, 1395. 4. Morris, E. V.; Edwards, C. M. J. Cell. Physiol. 2018, DOI:10.1002/jcp.26884.
food intake, preventing and treating of obesity, antipsychoticinduced weight gain, type 2 diabetes, drug and alcohol addition, sleep disorders, urinary incontinence, and so forth. Definitions. n is 1 or 2; X2 is N or CR2; X3 is N or CR3; X4 is N or CR4; R6, R7, and R8 is hydrogen or C1−C6 alkyl; R9 is hydrogen or C1−C6 alkyl. R1, R2, R3, and R4 is hydrogen or C1−C6 alkyl. Key Structures.
■
AUTHOR INFORMATION
Corresponding Author
*E-mail:
[email protected]. ORCID
Robert B. Kargbo: 0000-0002-5539-6343 Notes
The author declares no competing financial interest.
Biological Assay: Inositol Phosphate (IP) Accumulation Assays. The biological activities of compounds in this invention were tested using IP accumulation assay. HEK293 cells that expressed recombinant 5-HT2 receptors were radiolabeled with [3H]inositol phosphates and measured by a PerkinElmer scintillation counter. Compound 152 showed a significant decrease in cumulative food intake relative to placebo in the male Sprague− Dawley rat. Biological Data. The Table below shows observed IP accumulation EC50 values for the compounds of this Patent Highlight that were tested at the 5-HT2C, 5-HT2B, and 5-HT2A receptors.
B
DOI: 10.1021/acsmedchemlett.8b00328 ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX
